197 related articles for article (PubMed ID: 38749438)
1. [Targeted therapies in the management of malignant lymphoma - is the end of conventional chemotherapy near?].
Hellmuth JC; Koch R; Weigert O
Dtsch Med Wochenschr; 2024 May; 149(11):621-629. PubMed ID: 38749438
[TBL] [Abstract][Full Text] [Related]
2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
3. Lymphoma study group of JCOG.
Tsukasaki K; Tobinai K; Hotta T; Shimoyama M
Jpn J Clin Oncol; 2012 Feb; 42(2):85-95. PubMed ID: 22147803
[TBL] [Abstract][Full Text] [Related]
4. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
5. Novel targeted therapeutic agents for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.
Barth MJ; Minard-Colin V
Br J Haematol; 2019 Jun; 185(6):1111-1124. PubMed ID: 30701541
[TBL] [Abstract][Full Text] [Related]
6. Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma.
Makita S; Hosoba R; Tobinai K
Expert Opin Drug Saf; 2020 Sep; 19(9):1105-1120. PubMed ID: 32715803
[TBL] [Abstract][Full Text] [Related]
7. Denileukin diftitox as novel targeted therapy in non-Hodgkin's lymphoma.
Walker PL; Dang NH
Clin J Oncol Nurs; 2004 Apr; 8(2):169-74. PubMed ID: 15108419
[TBL] [Abstract][Full Text] [Related]
8. Management of indolent B-cell Lymphomas: A review of approved and emerging targeted therapies.
Smyth E; Cheah CY; Seymour JF
Cancer Treat Rev; 2023 Feb; 113():102510. PubMed ID: 36634434
[TBL] [Abstract][Full Text] [Related]
9. Current targeted therapies in lymphomas.
Chung C
Am J Health Syst Pharm; 2019 Oct; 76(22):1825-1834. PubMed ID: 31580408
[TBL] [Abstract][Full Text] [Related]
10. Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development.
Kubuschok B; Trepel M
Expert Opin Drug Discov; 2017 Jul; 12(7):733-745. PubMed ID: 28494631
[TBL] [Abstract][Full Text] [Related]
11. [Development of mechanism-based targeted therapies for malignant lymphoma].
Rai S
Rinsho Ketsueki; 2020; 61(9):1266-1274. PubMed ID: 33162525
[TBL] [Abstract][Full Text] [Related]
12. New targeted therapies for malignant lymphoma based on molecular heterogeneity.
Horn H; Staiger AM; Ott G
Expert Rev Hematol; 2017 Jan; 10(1):39-51. PubMed ID: 27918211
[TBL] [Abstract][Full Text] [Related]
13. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
[TBL] [Abstract][Full Text] [Related]
14. Novel therapies in mantle cell lymphoma: a pathway to chemotherapy-free strategies.
Nastoupil LJ; Koff JL; Flowers CR
Oncology (Williston Park); 2013 Oct; 27 Suppl 2():8-12. PubMed ID: 25374999
[TBL] [Abstract][Full Text] [Related]
15. Non-Hodgkin's B-cell lymphoma: advances in molecular strategies targeting drug resistance.
Maxwell SA; Mousavi-Fard S
Exp Biol Med (Maywood); 2013 Sep; 238(9):971-90. PubMed ID: 23986223
[TBL] [Abstract][Full Text] [Related]
16. Molecularly targeted therapies for relapsed and refractory peripheral T-cell lymphomas.
Epstein-Peterson ZD; Horwitz SM
Semin Hematol; 2021 Apr; 58(2):78-84. PubMed ID: 33906725
[TBL] [Abstract][Full Text] [Related]
17. Novel Insights into Membrane Targeting of B Cell Lymphoma.
de Winde CM; Elfrink S; van Spriel AB
Trends Cancer; 2017 Jun; 3(6):442-453. PubMed ID: 28718418
[TBL] [Abstract][Full Text] [Related]
18. The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas.
Macalalad AR; McAuliffe M; Yang H; Kageleiry A; Zhong Y; Wu EQ; Shonukan O; Bonthapally V
Curr Med Res Opin; 2015 Mar; 31(3):537-45. PubMed ID: 25598441
[TBL] [Abstract][Full Text] [Related]
19. Targeting B-cell non Hodgkin lymphoma: New and old tricks.
Solimando AG; Ribatti D; Vacca A; Einsele H
Leuk Res; 2016 Mar; 42():93-104. PubMed ID: 26818572
[TBL] [Abstract][Full Text] [Related]
20. Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia.
Vidal L; Gafter-Gvili A; Gurion R; Raanani P; Dreyling M; Shpilberg O
Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD009045. PubMed ID: 22972131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
